Capital raises and 2023 results among the healthcare news for the week

NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks.

The Nordic biotech and healthcare stocks continue to create opportunities for investors with a risk appetite. In the past week, Saniona and Evaxion Biotech raised capital, while Ascendis Pharma and Expres2ion Biotech announced their 2023 results. No companies reported any pipeline development.

7 of the 20 companies had a positive share price development the past week and 8 companies have had a positive share price performance year-to-date. Y-mAbs Therapeutics is the best-performing Danish stock year-to-date with a 92% return and Odinwell AB was the best investment last week.

Stay tuned to the developments of impact companies and stocks in the Nordics with the NORDIC | IMPACT newsletter that helps you to invest more sustainably in the businesses of tomorrow.


Ascendis Pharma

Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results (Link)

Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (Link)


No news the past week


No news the past week

CS Medica

No news the past week


No news the past week

Evaxion Biotech

Evaxion Announces Closing of $15 Million Public Offering (Link)

Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement (Link)


ExpreS2ion announces financial results for the fourth quarter and full-year 2023 (Link)


No news the past week


No news the past week


No news the past week

Initiator Pharma

No news the past week

IO Biotech

No news the past week

Pila Pharma

No news the past week


Saniona publishes outcome in rights issue (Link)

Scandion Oncology

No news the past week

SynAct Pharma

SynAct Pharma AB will publish its Q4 report for 2023 on February 23 at 07.30 CET. (Link)

Notice of extraordinary general meeting in SynAct Pharma AB (Link)


No news the past week

Zealand Pharma

No news the past week

Y-mAbs Therapeutics

No news the past week


No news the past week



On average, the Danish biotech and healthcare stocks delivered a negative share price performance of the past week of -3.5%. The most notable news were capital raises by Saniona and Evaxion Biotech rasing 88.9 MSEK 15 MUSD respectively. Ascendis Pharma and Expres2ion Biotech also announced their 2023 results. There were no major pipeline development in any of the companies. The best stocks year-to-date are Y-mAbs Therapeutics, CS Medica, and Expres2ion Biotech Holding with 58-92% increases already after six weeks of trading. Overall the Danish biotech and healthcare stocks are in positive territory this year with a year-to-date return of 5.6%.

Read more about Curasight (in Danish): Positive studiedata mod lungekræft styrker Curasights stærke kursudvikling

Overview of share price developments the past week, year-to-date, and last twelve months


In the past week, the all-Nordic index Kapital Partner Nordic Healthcare Index (KPHC) fell 1.7% to 63.10. The index was previously recovering from the all-time low in October of 57.12 but is now on a downward trajectory again. In the past 12 months, it has significantly underperformed relative to large caps, while the venture/small cap Kapital Partner Nordic Growth Exchanges index (KPNGX) has followed the KPHC index’s downward trajectory.

The index development for Kapital Partner Healthcare Index the past 12 months

The KPHC index includes all Nordic healthcare stocks. This means both Novo Nordisk and Genmab as well as Curasight.

31-46% in weekly return for the three best-performing Nordic biotech & healthcare stocks the past week

Odinwell AB (46%) (Nordnet) specializes in the development of medical devices addressed to wound care management. The company is developing a platform for wound care with associated technological aids to analyze and facilitate the process around wound care management. In addition to the main business, associated services are also offered.

Acarix AB (37%) (Nordnet) has developed a technology that enables the identification of coronary heart disease. The company’s product is a non-invasive test that is put with a note on the patient to analyze sound from the heart. Operations are mainly conducted in the Nordic market. The company was founded in 2009 as a spin-off from Coloplast. 

Qlife Holding AB (31%) (Nordnet) is a medical technology company. The company specializes in the research and development of IVD units. The units are used as biomarker tests in blood and are used as a complement to other tests in healthcare. Cooperation is also carried out with other actors on the market. 

Sources: Refinitiv & Nordnet


Udvalgte investeringscases

Ønsker du at modtage et af vores nyhedsbreve? Udfyld venligst formularen nedenunder.

  • Investeringscases – Nyhedsbreve med top aktuelle investeringscases fra de nordiske vækstbørser og life science sektoren, og ugentlige markedsopdateringer..
  • Børsnoteringer – Opdateringer på nye og igangværende børsnoteringer i Skandinavien samt resultaterne af dem. (Nyhedsbrev fra   
  • Nyheder – Nyheder fra og om Kapital Partner, herunder indsigt om kapitalmarkederne og børsnoteringer samt invitation til investormøder og- arrangementer.
  • Danish Biotech Weekly – Ugentlig opdatering med nyheder og kursudvikling for alle danske, børsnoterede selskaber uanset hvilket land eller børs de er noteret

*Hvis du ønsker information om vores kommende investeringsforening med fokus på de nordiske vækstbørser, herunder mulighed for at investere, så tilmeld dig nyhedsbrevet Nyheder.


Ønsker du at være en del af Kapital Partners investornetværk, hvor du får adgang til investeringer i selskaber og emissioner, samt indbydelse til investorrettede arrangementer
udfyld venligst formularen her.

Udvalgte cases

Del indlægget på sociale media eller på email.